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Abstract
To identify new risk variants for cutaneous basal cell carcinoma, we performed a genome-wide
association study of 16 million SNPs identified through whole-genome sequencing of 457
Icelanders. We imputed genotypes for 41,675 Illumina SNP chip-typed Icelanders and their
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relatives. In the discovery phase, the strongest signal came from rs78378222[C] (odds ratio (OR)
= 2.36, P = 5.2 × 10−17), which has a frequency of 0.0192 in the Icelandic population. We then
confirmed this association in non-Icelandic samples (OR = 1.75, P = 0.0060; overall OR = 2.16, P
= 2.2 × 10−20). rs78378222 is in the 3′ untranslated region of TP53 and changes the AATAAA
polyadenylation signal to AATACA, resulting in impaired 3′-end processing of TP53 mRNA.
Investigation of other tumor types identified associations of this SNP with prostate cancer (OR =
1.44, P = 2.4 × 10−6), glioma (OR = 2.35, P = 1.0 × 10−5) and colorectal adenoma (OR = 1.39, P
= 1.6 × 10−4). However, we observed no effect for breast cancer, a common Li-Fraumeni
syndrome tumor (OR = 1.06, P = 0.57, 95% confidence interval 0.88–1.27).
Basal cell carcinoma (BCC) is the most common cancer in people of European ancestry. Sun
exposure is the primary risk factor for BCC, but genetic predisposition also plays a
substantial role1,2. High penetrance mutations in Hedgehog pathway genes (PTCH1, PTCH2
and SUFU) cause Gorlin syndrome, also known as basal cell nevus syndrome1. Candidate
gene and genome-wide association studies have shown that common, low-penetrance
susceptibility alleles exist at MC1R and several other loci3–7.
Previously, we described a large genome-wide association study of the Icelandic population
using common SNPs and showed how genotypes can be phased over long distances8,9. For
BCC, we initially generated Illumina SNP chip data for 1,366 affected individuals (cases)
and 40,309 controls. Haplotype association analysis based on long-range phasing showed
that several 0.3-cM haplotypes at 17p13 were strongly associated with BCC. The most
significant signals were produced by haplotype A6 (OR = 2.04, P = 2.0 × 10−10), spanning
the region chr17: 7,186,095–7,425,536 and by a highly correlated haplotype, A8 (OR =
2.00, P = 3.0 × 10−10), spanning an adjacent region, chr17:7,431,901–7,680,389. The region
covered by these haplotypes is illustrated in Figure 1.
To search for variants that might not be covered well by the chips, we used high-capacity
DNA sequencing techniques to sequence the entire genomes of 457 Icelanders to an average
depth of over 10× (Online Methods), which identified approximately 16 million SNPs. To
ensure that all the rare risk alleles that might be carried on the A6 or A8 backgrounds would
be sequenced, we included ten individuals who carried these haplotypes among the 457
individuals selected for sequencing. Using imputation assisted by long-range haplotype
phasing, we used the sequence data to determine the genotypes of the 16 million SNPs in the
41,675 Icelanders who had been genotyped on the SNP chips. Moreover, knowledge of
Icelandic genealogy allowed us to propagate genotypic information into individuals for
whom we have neither SNP chip nor sequence data, a process we refer to as ‘genealogy-
based in silico genotyping’. We refer to the combined method of imputing sequence-derived
data into phased chromosomes from chip-typed individuals and using genealogy-based in
silico genotyping to infer the sequence of ungenotyped individuals as ‘two-way imputation’
(Supplementary Note).
We conducted a two-way-imputation–based genome-wide BCC association analysis of the
16 million SNPs, which we designated the ‘discovery phase’. This analysis identified a
number of SNPs with strong associations in the region covered by the two haplotypes. The
strongest signal (OR = 2.36, P = 5.2 × 10−17) came from rs78378222, located in the 3′
untranslated region of TP53 (Fig. 1 and Table 1). This signal was not only the strongest in
the region covered by the two candidate haplotypes, but it was also the strongest signal of
the 16 million SNPs observed genome wide. The minor (C, at risk) allele is present in the
Icelandic population at a frequency of 0.0192. There was no deviation from Hardy-
Weinberg equilibrium, and we observed C/C homozygotes (although they are rare), so the
variant is not recessive lethal. The SNP was not on the Illumina chips and is not in
HapMap2 or HapMap3. The best on-chip tag SNP was rs4796305, which produced only a
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modest signal (OR = 1.18, P = 0.0024, minor allele frequency = 0.119, r2 = 0.15). A
quantile-quantile plot is shown in Supplementary Figure 1. Aside from the 17p13 locus, all
other SNPs that surpassed the P = 3.0 × 10−9 Bonferroni-adjusted threshold for genome-
wide significance were in previously published loci5,6.
To further investigate the rs78378222 association, we conducted a follow-up phase. The
design of the discovery and follow-up phases is detailed in Supplementary Figure 2. We
devised a Centaurus10 single-track assay for rs78378222 and used it to genotype all
available samples from Icelandic cases with BCC (n = 2,322) and 7,200 controls. Among
these, 1,044 out of the 2,322 single-track genotyped cases had not previously been
genotyped by the Illumina chip. An association analysis with these 1,044 cases and 7,200
controls yielded OR = 2.19 and P = 3.2 × 10−7 (Table 1, see the Iceland follow-up single-
track genotyped category). Note that this is not a fully independent replication of the
discovery phase result, as some of the individuals who had been assigned genealogy-based
in silico genotypes in the discovery phase were single-track genotyped in the follow-up
phase (Supplementary Fig. 2). We then repeated the two-way-imputation–based analysis
using a non-overlapping sample that excluded the 1,044 single-tracked cases (Table 1, see
the Iceland follow-up two-way–imputation category). Combining the results from the two
follow-up groups provided strong evidence for the association of rs78378222 with BCC (OR
= 2.25, P = 5.4 × 10−19; Table 1, see the Iceland follow-up phase combined category).
Association based on all 2,322 cases who had been single-track genotyped (irrespective of
whether or not they had been chip typed) produced comparable results (Supplementary
Table 1).
We then typed rs78378222 in replication samples from Denmark, eastern Europe and Spain
(the replication sets are described in Supplementary Table 2). We found the risk allele in all
the populations tested, with frequencies that seemed to decline with each population’s
distance from Iceland (Table 1). Combined, the evidence for replication of the BCC
association in non-Icelandic samples was significant and showed no evidence of
heterogeneity (OR = 1.75, P = 0.0060, P of heterogeneity (Phet) = 0.27; Table 1). Combined
with the Icelandic follow-up phase data, the overall association was highly significant (OR =
2.16, P = 2.2 × 10−20).
The second strongest signal in the genome originated from a previously unreported SNP
(designated chr17:7,640,788; OR = 2.41, P = 1.1 × 10−13) which was also in the region
covered by the two candidate haplotypes (Fig. 1). Based on single-track genotyping of 2,281
cases and 6,858 controls for both SNPs, chr17:7,640,788 was correlated (r2 = 0.61) with
rs78378222 and so may capture the same signal. When adjusted for the effect of
rs78378222, there was no residual signal from chr17:7,640,788 (ORadj = 1.07, Padj = 0.72),
whereas rs78378222 remained significant after adjustment for chr17:7,640,788 (ORadj =
2.00, Padj = 3.0 × 10−5). Therefore, we did not investigate chr17:7,640,788 further. A
common germline variant in TP53 (rs1042522, p.Pro72Arg) has been studied extensively for
cancer susceptibility, generally with equivocal results11. We saw no evidence that
rs1042522 was associated with BCC (OR = 1.00, P = 0.98). We confirmed this by single-
track genotyping. Thus, it appears that p.Pro72Arg does not confer risk of BCC and is
unrelated to the rs78378222 signal.
p53 is induced by ultraviolet irradiation of skin and is a primary mediator of the tanning
response12,13. We looked for associations between rs78378222 and sensitivity of skin to sun
in 11,131 samples from Iceland and The Netherlands14,15. There was no significant
association between rs78378222[C] and self-reported sun sensitivity (Fitzpatrick score I and
II compared to III and IV; OR = 1.14, P = 0.23, 95% confidence interval (CI) 0.92–1.41).
We also noted that rs78378222[C] was somewhat more frequent in individuals with tumors
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at sun-exposed sites (0.0412) than in those with tumors at non–sun-exposed sites (0.0302);
however, this difference was not significant (P = 0.18).
Inspection of the sequence surrounding rs78378222 indicated that it occurs in the sole
polyadenylation signal of TP53, with the risk-associated variant changing the sequence
AATAAA to AATACA, thus disrupting the signal sequence. This class of mutations was
first observed in the polyadenylation signal of HBA2 (encoding alpha 2 globin), leading to
alpha-thalassemia16. We obtained RNA from blood and adipose tissue from rs78378222[A/
C] heterozygotes and rs78378222[A/A] homozygotes. Using RT-PCR with primers internal
to the TP53 mRNA, we observed that rs78378222[A/C] heterozygotes expressed somewhat
less TP53 transcript than wild-type homozygotes (P = 0.041; Supplementary Fig. 3a). To
investigate polyadenylation site usage of wild-type and variant TP53, we selected total RNA
samples from rs78378222[A/C] heterozygotes and carried out 3′ rapid amplification of
complementary DNA ends (RACE; Supplementary Fig. 3b). Amplification using a TP53
gene-specific forward primer produced a band of 1.3 kb, which is the expected length of
correctly terminated mRNA (Supplementary Fig. 3c). However, sequencing of this band
indicated that correctly terminated polyA(+) mRNAs were produced predominantly from the
wild-type allele, with 73% of mRNAs containing the wild-type A allele and 27% containing
the variant C allele (P = 1.6 × 10−6; Supplementary Fig. 3c). We then carried out RT-PCR
using a ‘run-on’ reverse primer, located in the genomic sequence approximately 320 bp
beyond the normal 3′ end of TP53 (Supplementary Fig. 3b). Sequencing of RT-PCR
products from heterozygotes showed that this RNA species was comprised almost entirely
of variant C allele transcripts (Supplementary Fig. 3d). Taken together, these data suggest
that the rs78378222[C] variant impairs proper termination and polyadenylation of the TP53
transcript.
Next, we searched for associations between rs78378222 and 20 major tumor types by cross-
referencing genotypes to the Icelandic Cancer Registry and national pathology records.
After correcting for multiple phenotype testing, we observed significant associations for
prostate cancer, brain cancers and colorectal adenoma (but not colorectal cancer)
(Supplementary Table 3). We conducted a follow-up phase in an attempt to get further
evidence of these associations. The follow-up phase was analogous to that described in
Supplementary Figure 2, and the sample numbers are detailed in Supplementary Table 4.
We directly genotyped rs78378222 in all available Icelandic cases with prostate cancer,
colorectal adenoma or brain cancer and determined follow-up phase two-way–imputation-
based and single-track genotype-based association values (Table 2). For prostate cancer, we
further genotyped replication samples from five countries. The association with prostate
cancer outside Iceland was significant (OR = 1.63, P = 1.1 × 10−4), as was the combined
Iceland follow-up and replication sample result (OR = 1.44, P = 2.4 × 10−6; Table 2). For
the colorectal adenoma follow-up phase, single-track genotyping gave a comparable result
to two-way imputation, and the combined analysis yielded a significant association result
(OR = 1.39, P = 1.6 × 10−4; Table 2 and Supplementary Table 1). However, we still
observed no significant association with colorectal cancer after genotyping replication
samples from four countries (combined OR = 1.06, P = 0.51, 95% CI 0.89–1.27;
Supplementary Table 5). This raises the possibility that rs78378222[C] might predispose to
colorectal adenomas with a low propensity for progression to invasive cancer.
The discovery two-way–imputation category of ‘all brain cancers’ contained meningiomas
(International Classification of Diseases (ICD) 10 code C70) and gliomas (C71–C72). When
glioma and meningioma were considered separately, the association appeared stronger for
glioma (OR = 2.50, P = 0.0055) than for meningioma (OR = 1.48, P = 0.36). Although this
difference was not significant (P = 0.88), we focused on glioma in the follow-up phase
(Table 2). In Iceland, the follow-up phase yielded a suggestive association with glioma (OR
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= 2.36, P = 0.0036). This was confirmed in two case-control samples of adult glioma from
the United States (OR = 2.34, P = 9.2 × 10−4). Combined with the Icelandic data, we
obtained firm evidence that rs78378222[C] was associated with glioma (OR = 2.35, P = 1.0
× 10−5; Table 2).
We also investigated potential associations with melanoma (because of the link between
rs78378222 and skin cancer risk) and breast cancer (because of the involvement of TP53
mutations in Li-Fraumeni and Li-Fraumeni–like syndromes). We did not see any convincing
evidence that rs78378222 confers risk of either of these tumors (OR = 1.07, P = 0.64, 95%
CI 0.81–1.42 for melanoma and OR = 1.06, P = 0.57, 95% CI 0.88–1.27 for breast cancer;
Supplementary Table 5). There was no evidence of specific associations with estrogen-
receptor–negative breast cancer (OR = 1.15, P = 0.61) or high-risk breast cancer (defined as
an age at diagnosis under 50 or a history of multiple primary breast cancers; OR = 0.87, P =
0.36).
Given its central role in tumor biology and the high frequency of somatic mutation17,
intensive efforts have been devoted to searching for germline cancer susceptibility variants
in TP53. Aside from gain-of-function mutations typically found in Li-Fraumeni and Li-
Fraumeni–like syndromes, no germline variants of TP53 have so far been implicated
reproducibly in cancer predisposition11,18. Cross-referencing the Icelandic genealogical
database with cancer registry records did not reveal any rs78378222[C] carriers with family
histories fitting the criteria of Li-Fraumeni or Li-Fraumeni–like syndrome19,20. TP53
mutations leading to Li-Fraumeni and Li-Fraumeni–like syndromes are rare, occurring in 1
in 5,000 to 1 in 20,000 births21,22. Although the penetrance of rs78378222[C] for the
cancers it affects is much less, carriers are expected in frequencies of up to 4% in some
populations. The effect of rs78378222[C] on 3′-end processing suggests a new mechanism
by which TP53 may promote oncogenesis, with a distinctive spectrum of tumors being
affected.
URLs. Picard version 1.17, http://picard.sourceforge.net/.
Methods
Methods and any associated references are available in the online version of the paper at
http://www.nature.com/naturegenetics/.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Overview of single-point SNP association data obtained from genomic sequencing in the
17p13 region covered by haplotypes A6 and A8. The region shown is chr17:7,186,095–
7,680,389 (HG18 Build 36). The upper panel shows BCC association P values for SNPs in
the region identified by whole-genome sequencing of 457 individuals. We determined
association by two-way imputation (see the text for details); only SNPs with P < 0.01 are
plotted. The positions of the TP53 SNP rs78378222 and the newly discovered SNP giving
the second-highest signal in the region (chr17:7,640,788) are indicated. The locations of
UCSC genes in the region are shown in the middle panel. The lower panel shows
recombination rates calculated as described previously23 from HapMap2 release 22 data.
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